Guggenheim upgrades Surrozen to Buy after ‘encouraging’ SZN-043 data

As previously reported, Guggenheim upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Recent Phase 1b data for SZN-043, the company’s lead asset for liver disease, was “encouraging,” says the analyst, who is “interested to see if the company can maintain below 15-20% 30-day mortality at higher doses.” Additional data are expected in the first half of 2025, the analyst noted.